United States

Ocugen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

Lead Product(s): NR2E3-AAV

Therapeutic Area: Ophthalmology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

Data support nuclear hormone receptor gene NR2E3 as genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases and potentially serve as a broad-spectrum therapy.

Graybug Vision

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

WRIB

Participation Not Confirmed

Update your events

Graybug Vision Presents Preclinical Results for GB-401

Lead Product(s): GB-401

Therapeutic Area: Ophthalmology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2020

Details:

The study showed that GB-401 achieved sustained ocular drug levels and reduced IOP in experimental animal models after a single intravitreal or subconjunctival injection.